The Chernobyl Nuclear Power Plant (CNPP) accident on 26th April 1986 was the worst nuclear disaster in history. The accident caused the release of a large amount of radionuclides into the environment (United Nations Scientific Committee on the Effects of Atomic Radiation, 2011). The fallout, which contained both short-lived radionuclides consisting mostly of iodine-131 (131I) and long-lived radionuclides made up largely of cesium-137 (137Cs) (Christodouleas et al., 2011), exposed a great number of inhabitants living in contaminated areas now in Ukraine, Belarus, and the Russian Federation to internal radiation of the thyroid gland through the ingestion of contaminated foods containing 131I (United Nations Scientific Committee on the Effects of Atomic Radiation, 2011). Several years after the accident, the incidence of childhood thyroid cancer had dramatically increased in the population living in those areas and was strongly related to this 131I exposure (Cardis et al., 2005; Demidchik, Saenko & Yamashita, 2007; Zablotska et al., 2011). Between 1991 and 2005, 5,127 cases of thyroid cancer were reported in residents exposed as children under 14 years old in 1986 (6,848 cases in those under 18), according to the UNSCEAR report (United Nations Scientific Committee on the Effects of Atomic Radiation, 2011).
On the other hand, several studies have been conducted regarding the relationship between radiation exposure and thyroid autoimmunity and benign thyroid diseases, but the results remain inconsistent (Ito et al., 1995; Vykhovanets et al., 1997; Pacini et al., 1998; Vermiglio et al., 1999). Screening studies targeting individuals under 18 years old at the time of the accident showed a significant association between thyroid 131I dose and the prevalence of subclinical hypothyroidism (Ostroumova et al., 2009; Ostroumova et al., 2013), but not with Autoimmune Thyroiditis (AIT) (Tronko et al., 2006; Ostroumova et al., 2009; Ostroumova et al., 2013). Agate et al. (2008) also reported a higher prevalence of thyroid dysfunction and TPOAb without autoimmune thyroiditis in children living in the contaminated region 13–15 years after the accident, compared to non-contaminated Belarusian settlements (Agate et al., 2008). Almost thirty years has passed since the Chernobyl accident. The residents who lived through the accident in childhood are now adults and the situation might have evolved. The purpose of this study was to evaluate the association of internal radiation exposure to 131I and the prevalence of anti-thyroid autoantibodies (ATAs) and benign thyroid disease among young adults living in the contaminated area of Ukraine, more than 25 years after the accident.
Material and Methods
This study was conducted primarily at the Korosten Inter-Area Medical Diagnostic Center (“the center”), Korosten, Zhitomir region, Ukraine. This area is located 120 km southwest of the CNPP and was heavily affected by the accident. The estimated average 131I thyroid doses in children and adolescents living in this region at the time of the accident was 0.15–0.65 Gy (United Nations Scientific Committee on the Effects of Atomic Radiation, 2011).
For study participants, we recruited two groups of young adults who visited the center between June 2012 and January 2014 for their annual health screening. The first group consisted of young adults (n = 300) born between 1st January 1981 and 26th April 1986 (age 0–5 years on 26th April 1986) who lived in the region at the time of the accident and were not evacuated (group 1). This group was considered to have experienced internal 131I radiation exposure. The second group consisted of sex-matched young adults (n = 300) born between April 1987 and December 1991 (more than one year after the accident) and residing in the Zhitomir region after the accident (group 2). This group was considered to have not experienced internal 131I radiation exposure; since the half-life of 131I is about eight days, the 131I had decayed within a few months after the accident and any effect of 131I should have been extremely low when they were born. Young adults who had a history of thyroid cancer or had undergone thyroid lobectomy were excluded. The study protocol was approved by the center’s Institutional Review Board (No. 002) and the ethical committee of Nagasaki University Graduate School of Biomedical Sciences (No. 12122865). Prior to the study, written informed consent was obtained from all participants.
Blood samples were collected for measurement of Free Triiodothyronine (FT3), Free Thyroxin (FT4), Thyroid-Stimulating Hormone (TSH), Antithyroglobulin Antibodies (TGAb), and Antithyroid Peroxidase Antibodies (TPOAb). Serum FT3, FT4, TSH, TGAb, and TPOAb levels were measured using a Stat Fax® 303 Plus Enzyme-Linked Immunosorbent Assay (ELISA) (Awareness Technology, Inc., Palm City, FL, USA). The laboratory reference range for FT3, FT4, and TSH were 1.4–4.2 ng/ml, 0.8–2 ng/ml, and 0.3–6.2 μIU/ml, respectively. TGAb values <8 IU/ml and TPOAb values <20 IU/ml were considered negative. We defined overt hypothiroidism as freeT4 <0.8 ng/dl and TSH >6.2 μIU/ml and subclinical hypothyroidism as freeT4 ≧0.8 ng/dl and TSH >6.2 μIU/ml.
Ultrasonography of the thyroid gland was performed in both groups using 8.5 MHz Nemio XG SSA-580A probes (Toshiba, Tokyo, Japan). Presence of nodules, cysts, and echostructure were recorded. The thyroid volume was calculated based on the formula, length × width × depth × 0.479 described by Brunn et al. (1981). Finally, we defined goiter as thyroid volume larger than 25 ml in men and 18 ml in women.
The 137Cs body burdens in both groups were measured using a whole-body counter (γ-spectrometer, model 101, equipped with a collimator; Aloka Co., Ltd., Tokyo, Japan). The detectable 137Cs body burden was 270 Bq/body. Participants who did not have any 137Cs exposure were defined as be “0 Bq.”
Data are expressed as means plus Standard Deviations (SDs) and medians. Differences in age, FT3 and FT4 concentrations, and thyroid volumes between groups were evaluated using t-tests. TSH concentration was distributed in a skewed manner, so logarithmic transformation was performed for the analysis. FT3 and FT4 concentrations adjusted for age and thyroid volumes adjusted for body weight were compared by analysis of covariance between the groups. The difference between groups for 137Cs body burden was evaluated by a Mann-Whitney’s U-test. Frequencies of positive TGAb, TPOAb, thyroid nodules, and goiter were evaluated using the χ2-test. Frequencies of hypothyroidism were evaluated using Fisher’s exact test. We used logistic regression analysis to assess the association between the prevalence of ATAs, goiter, and nodules and 131I exposure, age, and sex. All statistical analyses were performed using SPSS software, v.22 for Mac (SPSS Japan, Tokyo, Japan). The p values of less than 0.05 were considered statistically significant.
The characteristics of participants, functional thyroid outcomes and 137Cs body burdens are summarized in Table 1. The mean age of groups 1 and 2 was 28.3 and 23.0 years old at examination, respectively. Each group included 237 females (79%). The median 137Cs body burden was below the detection limit in both groups, and no significant difference was noted between the groups (p = 0.261). Most participants had FT3 and FT4 concentrations within the normal range, but FT4 concentrations were significantly higher in group 2 (p = 0.014) and FT3 concentrations adjusted for age were significantly higher in group 2 (p = 0.016). Median TSH concentrations in groups 1 and 2 were 1.08 μIU/ml and 1.22 μIU/ml, respectively, but this difference was not statistically significant (p = 0.183). A few subclinical or overt hypothyroidism cases were observed, all of them were ATA-positive. The prevalence of subclinical hypothyroidism was not significantly different between the groups (p = 0.093). Only three and one overt hypothyroidism cases were observed in groups 1 and 2, respectively; the prevalence was also not significantly different (p = 0.320).
|Group 1 (n = 300)||Group 2 (n = 300)||p value||Adjusted p value|
|Age (at the examination)||28.3 ± 1.4||23.0 ± 1.4||<0.001||–|
|Female, n (%)||237 (79)||237 (79)||–||–|
|Free T3, pg/ml||2.66 ± 1.18||2.75 ± 0.99||0.333||0.016*|
|Free T4, ng/dl||1.33 ± 0.39||1.39 ± 0.30||0.014*||0.074|
|TSH, μIU/ml||1.08 (0.76–1.75)||1.22 (0.81–1.77)||0.183||–|
|Log(TSH)||0.02 ± 0.44||0.04 ± 0.40||0.308||0.602|
|Overt hypothyroidism, n||3||1||0.320||–|
|Subclinical hypothyroidism, n||7||2||0.093||–|
|Thyroid volume, ml||15.93 ± 7.00||15.74 ± 5.29||0.718||0.204|
|137Cs body burden, Bq/kg||0 (0–49.65)||0 (0–159.34)||0.261||–|
Age, FreeT3, FreeT4, log TSH and thyroid volume are shown as mean ± SD. TSH is shown as median(IQR) and 137Cs body burden is shown as median (minimum-maximum). FreeT3, FreeT4 concentrations and log-TSH were adjusted for age and thyroid volume was adjusted for body weight between the groups were compared by analysis of covariance.
The prevalence of TGAb positive or TPOAb positive was not significantly higher in group 1 than in group 2 (TGAb positive: 11.7% vs 10.3%; p = 0.602, TPOAb positive: 17.3% vs 13.0%; p = 0.136, respectively, Fig. 1). The prevalence of TGAb and/or TPOAb positive was also not significantly different (21.0% vs 17.3%; p = 0.254). Logistic regression analysis adjusted for age and sex showed that only female gender was significantly correlated with TGAb, TPOAb, and TGAb and/or TPOAb positive prevalence (Table 2).
|TGAb||TPOAb||TGAb and/or TPOAb|
|Values||OR (95% CI)||p value||OR (95% CI)||p value||OR (95% CI)||p value|
|131I exposure (group 1/group 2)||2.029 (0.664–6.193)||0.214||2.529 (0.953–6.711)||0.062||1.943 (0.797–4.738)||0.144|
|Sex (female/male)||9.762 (2.355–40.472)||0.002*||2.749 (1.338–5.648)||0.006*||3.775 (1.852–7.698)||<0.001*|
|Age at examination||0.889 (0.747–1082)||0.260||0.896 (0.762–1.054)||0.184||1.943 (0.797–4.738)||0.144|
The mean thyroid volume was 15.93 ml for group 1 and 15.74 ml for group 2, with no significant difference of prevalence of goiter in the two groups (25.3% vs 26.7%; p = 0.780, Fig. 2). The prevalence of thyroid nodules was significantly higher in group 1 (16.3% vs 8.3%; p = 0.003); however, logistic regression analysis adjusted for age and sex showed that 131I exposure status was not correlated with nodule prevalence (OR = 0.782, 95% CI 0.263–2.320, p = 0.657), while age and female gender were significantly correlated with nodule prevalence (Table 3).
|Values||OR (95% CI)||p value||OR (95% CI)||p value|
|131I exposure (group 1/group 2)||0.782 (0.263–2.320)||0.657||2.085 (0.937–4.638)||0.072|
|Sex (female/male)||2.827 (1.257–6.357)||0.012*||2.323 (1.369–3.941)||0.002*|
|Age at examination||1.212 (1.011–1.452)||0.038*||0.860 (0.752–0.982)||0.026*|
In this study, we evaluated the association between internal 131I exposure and the prevalence of ATAs, thyroid function, and thyroid ultrasonography outcomes among young adults living in the contaminated area of Ukraine.
The positive impact of this study was to evaluate the relationship between the experience of internal 131I exposure in childhood and the occurrence of thyroid diseases more than 25 years after the accident. Additionally, by recruiting study participants who all lived in the same area, we were able to compare two groups that had similar internal 137Cs exposure levels and iodine status, which could have confounding effects on thyroid outcomes.
Several ecological studies conducted approximately 10 years after the accident have reported that prevalence of positive TPOAb and TGAb was significantly higher in children living in areas around the CNPP with greater contamination (Vykhovanets et al., 1997; Pacini et al., 1998; Vermiglio et al., 1999). On the other hand, a screening study conducted among 160,000 children aged 0–10 years at the time of the accident and living around the CNPP between 1991 and 1996 (5–10 years after the accident) within the framework of the Chernobyl Sasakawa Health and Medical Cooperation Project reported no significant relationship between the prevalence of TGAb and radiation exposure dose estimated by 137Cs body burden or with soil 131Cs contamination levels at sites where study participants were living (Saiko et al., 1997). Agate et al. (2008) recently evaluated the prevalence of positive TPOAb, TGAb and TSH concentrations in residents living in contaminated and non-contaminated areas of Belarus, Ukraine, and the Russian Federation 13–15 years after the accident, finding that the prevalence of positive TPOAb was significantly higher in adolescents exposed to radioactive fallout in Belarus, though not in Ukraine and the Russian Federation (Agate et al., 2008). In our study that conducted more than 25 years after the accident, we also did not find any significant difference in ATA prevalence between young adults in Ukraine exposed to radioiodine in childhood and young adults without exposure.
We showed that FT3 concentration adjusted for age was significantly higher in group 2, but did not find any significant increase in TSH concentration or in the prevalence of antibody-positive hypothyroidism in group 1. There are large cohort studies that reported the relationship between radiation exposure due to 131I by the accident at CNNP and hypothyroidism. Ostroumova et al. (2009) and Ostroumova et al. (2013) reported screening studies conducted in Ukraine and Belarus 10–17 years after the accident in individuals under the age of 18 years at the time of the CNPP accident, showing a significant association between 131I thyroid dose and the prevalence of subclinical hypothyroidism. However, excess odds ratio was higher in individuals with TPOAb ≤60 U/ml than in those with TPOAb >60 U/ml in both studies (Ostroumova et al., 2009; Ostroumova et al., 2013). In same study of Ukraine, Tronko et al. (2006) did not find any association between 131I thyroid dose and the prevalence of autoimmune thyroiditis, but the prevalence of elevated ATPO demonstrated a modest, significant association with 131I that was well described by several concave models (Tronko et al., 2006). As ecological study, Agate et al. (2008) reported that ATA prevalence in exposed Belarusian adolescents 13–15 years after the accident was much lower than the rate in their previous study of 6–8 years after the accident, suggesting a transient autoimmune reaction that did not trigger autoimmune disease and had no effect on thyroid function (Pacini et al., 1998; Agate et al., 2008). In our study, the sample size was small so that a careful evaluation is needed, but we did not find a significant increase of antibody-positive/negative hypothyroidism in the group exposed to 131I in their childhood, 25 years after the accident in Ukraine. The thyroid immune reaction to radiation exposure remains obscure. In atomic bomb survivors exposed to acute gamma radiation, a convex dose-response relation with antibody-positive hypothyroidism was observed (Nagataki et al., 1994), but was not found in a more recent study (Imaizumi et al., 2006). Hence, the autoimmune reaction to radiation exposure in thyroid may change over time, so that further long-period observation is needed to evaluate fully the dynamic of any relationship between radiation exposure and hypothyroidism and autoimmunity reaction in the thyroid.
Several studies on the role of radiation in the development of thyroid nodules among the cohorts of medically irradiated patients, residents exposed to fallout from nuclear testing, or atomic bomb survivors have been published (Ron & Brenner, 2010). Imaizumi et al. (2006) reported that among atomic bomb survivors, a significant linear dose-response relationship was observed for the prevalence of all solid nodules, not only malignant tumors, but also benign nodules and cysts (Imaizumi et al., 2006). On the other hand, in the Hanford nuclear test site study, there was no evidence that the incidence of benign thyroid nodules increased with dose (p = 0.68), with an estimated slope of −0.8%/Gy (95% CI, <−2.2%/Gy to 4.1%/Gy) (Davis et al., 2004). In the present study, the prevalence of thyroid nodules was significantly higher in group 1, but this difference disappeared after adjustment for age and sex. Age and sex are important factors influencing the development of benign thyroid nodules, and it has been reported that, even among people in their twenties, the prevalence of thyroid nodule is higher in female and older age cohorts (Reiners et al., 2004). In the Chernobyl Sasakawa Health and Medical Cooperation Project, the prevalence of thyroid nodules was also age-dependent and higher in girls than in boys, a fact that explains their higher incidence in older age groups (Panasyuk et al., 1997). In the present study, as the number of females was the same in both groups, the increase of thyroid nodule prevalence in group 1 might be due to aging rather than 131I exposure in their childhood.
In the present study, we have shown that female gender was significantly correlated with ATA prevalence and that age and female gender were significantly correlated with goiter. It is well known that aging and female gender are risk factors of high prevalence of ATAs and goiter (Hollowell et al., 2002; Reiners et al., 2004; Hoogendoorn et al., 2006).
This study has several limitations. The number of subjects was relatively small since it was conducted only among the population residing in Ukraine’s Zhitomir region and visiting the center for an annual health screening. As a reference, in the framework of the Chernobyl Sasakawa Health and Medical Cooperation Project, around 18,000 children aged 0–5 years old at the time of the accident were screened at the center from 1991–1996 (Yamashita & Shibata, 1997). Therefore, we screened around 1.6% of the number of patients who accessed the center in 1991–1996. Additionally, there might be a bias in the selection of study participants, as this study’s subjects were those residents who chose to visit the center and undergo health screening. Therefore, we need to evaluate carefully whether our data can be generalized to all eligible residents. We also could not evaluate individual thyroid doses because the data of thyroid dose was not available. However, The estimated average 131I thyroid doses in children living in this region at the time of the accident was reported as 0.15–0.65 Gy (United Nations Scientific Committee on the Effects of Atomic Radiation, 2011). And there is a ultrasound screening study of Belarusian school children living within 150 km of the CNNP showed high rates of thyroid cancer in those who were bone before the accident (exposed group; n = 31/9720, 0.32%), while no thyroid cancer was seen in those who were bone after the accident (unexposed group; n = 0/2409) (Shibata et al., 2001). This result suggested that the fallout of short-lived radionuclides from the CNPP accident affected to children who were bone before the accident but did not affect to children who were bone after the accident. Therefore, we considered that it might be possible to evaluate the relationship between the experience of exposure to 131I in childhood and prevalence of ATA and thyroid benign diseases even though the individual thyroid dose were not available.
In conclusion, we showed no increased prevalence of ATAs and benign thyroid diseases more than 25 years after the CNPP accident in young adults exposed to 131I fallout during their childhood. Long-term follow-up in the population living around the CNPP is needed to clarify the effects of radiation exposure on the autoimmunity reaction in the thyroid.